<?xml version="1.0" encoding="UTF-8"?>
<p>Despite robust SVR rates in most patients, the presence of HCV resistance–associated amino acid substitutions can result in lower cure rates in some patient groups, including genotype 1a/3, cirrhosis, and nonresponders to prior interferon‐based treatments. Developing strategies to detect and account for viral resistance to DAAs will be necessary, as with continued treatment, the population of chronically infected patients shifts toward treatment‐experienced, DAA‐refractory patients.</p>
